Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship.

European journal of internal medicine·2026
Same author

Fish-like aquatic propulsion studied using a pneumatically-actuated soft-robotic model.

Bioinspiration & biomimetics·2020
Same author

Hamostaseologie·2019
Same author

[Modern treatment of deep vein thrombosis and pulmonary embolism].

Der Internist·2019
Same author

Moderate increases in daily step count are associated with reduced IL6 and CRP in women with PCOS.

Endocrine connections·2018
Same author

Low incidence of heparin-induced skin lesions in orthopedic surgery patients with low-molecular-weight heparins.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2018
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

[Significance of platelet function tests].

Z Wolf1, H Mani, E Lindhoff-Last

  • 1Medizinische Klinik III, Schwerpunkt Angiologie und Hämostaseologie, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Deutschland. Zsuzsanna.Wolf@kgu.de

Der Internist
|August 12, 2010
PubMed
Summary
This summary is machine-generated.

Platelet function tests diagnose bleeding disorders and guide antiplatelet therapy. Standardized methods are needed to identify patients with poor response to aspirin or clopidogrel, improving treatment outcomes.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Experiment Videos

Last Updated: Jun 10, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

  • Hematology
  • Clinical Pathology
  • Pharmacology

Background:

  • Platelet function disorders can be congenital or acquired, impacting hemostasis.
  • Platelet aggregometry is the standard laboratory method for diagnosing platelet disorders.
  • Assessing platelet response to antiplatelet drugs like aspirin and clopidogrel is crucial for patient outcomes.

Purpose of the Study:

  • To highlight the diagnostic utility of platelet aggregometry.
  • To emphasize the clinical significance of non-response to antiplatelet therapy.
  • To identify the need for standardized methods in assessing platelet inhibition.

Main Methods:

  • Utilizing platelet aggregometry with various agonists (ADP, collagen, arachidonic acid, ristocetin).
  • Reviewing studies correlating laboratory assessment of platelet non-response with clinical outcomes.
  • Analyzing the importance of adjusting antiplatelet therapy based on platelet inhibition levels.

Main Results:

  • Platelet aggregometry is a key diagnostic tool for platelet function.
  • Laboratory assessment of non-response to aspirin or clopidogrel is linked to adverse events.
  • Low platelet inhibition necessitates adjustments in antiplatelet therapy.

Conclusions:

  • Platelet aggregometry plays a vital role in diagnosing platelet disorders and monitoring antiplatelet therapy effectiveness.
  • Identifying patients with suboptimal platelet inhibition is critical for preventing adverse outcomes.
  • A standardized approach is still lacking for identifying patients who require adjusted antiplatelet regimens.